MLN-519: Millennium/PAION

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 333-341

  Di Napoli, Mario ^a   Papa, Francesca ^a  

^a SMDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CLASTOLACTACYSTIN BETA LACTONE; LACTACYSTIN BETA LACTONE; PN 05; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARM DISEASE; BRAIN ISCHEMIA; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPOTENSION; INFLAMMATORY DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION; TASTE AVERSION; WEIGHT REDUCTION;

ACETYLCYSTEINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MULTIENZYME COMPLEXES; MYOCARDIAL INFARCTION; NEUROPROTECTIVE AGENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 0038417000     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. 165898 A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL Proc Natl Acad Sci USA 1994 91 8 3358-3362
2. 202077 The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T Cell 1994 78 5 773-785
3. 202093 Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL Science 1995 268 5211 726-731
4. 273697 Active site-directed inhibitors of Rhodococcus 20 S proteasome. Kinetics and mechanism. McCormack T, Baumeister W, Grenier L, Moomaw C, Plamondon L, Pramanik B, Slaughter C, Soucy F, Stein R, Zuhl F, Dick L J Biol Chem 1997 272 42 26103-26109
5. 306910 PS-519, a novel proteasome inhibitor, reduces infarction in a rat model of ischemia/reperfusion brain injury. Phillips JB, Williams A, Dave JR, Elliott P, Tortella FC Abstr Soc Neurosci 1998 24 Pt 1 Abs 86.11
6. 319977 Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. Campbell B, Adams J, Shin YK, Lefer AM J Mol Cell Cardiol 1999 31 2 467-476 Proteasome inhibitors reduce neutrophil invasion of ischemic cardiac tissue and improve cardiac function.
7. 320224 ProScript receives SBIR grant for novel stroke treatment. ProScript Inc Press Release 1999 05 April
8. 324971 Neuroprotection for acute stroke: Making clinical trials work. Muir KW, Grosset DG Stroke 1999 30 1 180-182 Re-evaluates clinical trial methodology to optimize the likelihood of identifying efficacious drugs in the future. There is currently little evidence from animal focal ischemia models for the protection of white matter, glia or subcortical neurons. Thus the logical target population for initial clinical trials is patients with middle cerebral artery stroke involving the cerebral cortex.
9. 357114 Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D et al Proc Natl Acad Sci USA 1998 95 26 15671-15676
10. 357116 Proteasome inhibition: A novel mechanism to combat asthma. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J J Allergy Clin Immunol 1999 104 2 Pt 1 294-300 Demonstrates that proteasome inhibitors can reduce cellular infiltration in a model of asthma and that the effects are synergistic with steroids.
11. 358988 Trauma, shock, inflammation and sepsis: Pathophysiology, immune consequences and therapy - Fifth World Congress, Munich, Germany. IDdb author IDDB Meeting Report 2000 February 29-March 04
12. 378116 Pharmacology of Cerebral Ischemia - Eighth International Symposium (Part II), Marburg, Germany. IDdb author IDDB Meeting Report 2000 July 23-26
13. 387463 The novel proteosome inhibitor PS-519 is neuroprotective in two models of focal ischemia when administered hours post occlusion. O'Neill MJ, Rash K, Hsu MB, Bond A, Hicks CA, Murray TK, Elliot P, Clemens JA Abstr Soc Neurosci 2000 26 1 Abs 286.8
14. 392555 Millennium Pharmaceuticals Inc - Product pipeline. Millennium Pharmaceuticals Inc Company World Wide Web Site 2000 December 07
15. 396071 Proteasome inhibition measurements: Clinical application. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ Clin Chem 2000 46 5 673-683 This research paper provides a reliable method for studying the pharmacodynamics of proteasome inhibitors.
16. 413240 Proteasome targeting in transplantation. Faia KL, Gao W, Csizmadia V, Shemmeri N, Pien CS, Adams J, Elliott P, Hancock WW Am J Transplantation 2001 1 1 Abs 118
17. 427073 Targets newsletter: Emerging biotechs dive in Sept but positive events still move stocks. Reddoch JF Banc of America 2001 9 September 28
18. 427477 Millennium: UBS Warburg Global Life Sciences. Millennium Pharmaceuticals Inc Company Presentation 2001 October 11
19. 428419 Neuroprotection and ischemic brain injury in rats: Improved therapeutic window obtained with the proteasome inhibitor PS-519. Tortella FC, Williams A, Hale S, Elliot P Abstr Soc Neurosci 2001 27 Abs 864.8
20. 436401 Millennium Pharmaceuticals Inc. Hambrecht & Quist 2002 January 7-10 268
21. 437649 Wachovia Securities Integrated Oncology Conference. Millennium Pharmaceuticals Inc Company Presentation 2002 January 16
22. 441325 The proteasome: A new target for novel drug therapies. Elliot PJ, Ross JS Am J Clin Pathol 2001 116 5 637-646
23. 441557 Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, Chopp M Stroke 2001 32 12 2926-2931 MLN-519 improves neurological outcome and reduces infarct size. The combination treatment with MLN-519 and r-tPA extends the neuroprotective effect to at least 6 h after embolization.
24. 443497 Millennium and PAION to collaborate on stroke program. Millennium Pharmaceuticals Inc Press Release 2002 March 14
25. 448465 Transcription factor NF-κB is activated in neurons after focal cerebral ischemia. Stephenson D, Yin T, Smalstig EB, Hsu MA, Panetta J, Little S, Clemens J J Cereb Blood Flow Metab 2000 20 3 592-603
26. 450963 Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC Stroke 2001 31 7 1686-1693 MLN-519 mitigates infarction and improves neurological recovery in brain-injured rats, an effect partly caused by a reduction in the leukocyte inflammatory response.
27. 468308 Ischemic brain injury in rats: Attenuation of the inflammatory response with the proteasome inhibitor MLN519. Berti R, Moffett JR, Velarde LC, Elliott PJ, Yao C, Dave JR, Tortella FC Abstr Soc Neurosci 2002 28 Abs 695.11
28. 468345 Brain neuroprotection with a 10 hour delayed injection of the proteasome inhibitor MLN519 following MCAO in the rat. Elliott PJ, Williams AJ, Hale SL, Lu X-CM, Tortella FC Abstr Soc Neurosci 2002 28 Abs 695.2
29. 473268 Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH J Clin Invest 2002 109 5 671-679
30. 473270 Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD J Autoimmun 2000 14 3 205-211
31. 473271 Proteasome inhibitor PS519 reduces delayed-type hypersensitivity response via inhibition of carbohydrate synthesis of cutaneous lymphocyte-associated antigen (CLA) and T-cell rolling. Podda M, Pien C, Ludwig R, Schultz J, Hardt Weinelt K, Boehncke WH, Elliot PJ, Kaufmann R, Zollner TM J Invest Dermatol 2002 119 3 731
32. 473272 Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 2002 54 3 269-276 Proteasome inhibition is well tolerated by healthy individuals at levels that are maximally neuroprotective in experimental conditions.
33. 473273 Inhibition of proteasomes decreases superantigen-mediated T-cell activation and the severity of psoriasis in the SCID-Hu model. Zollner TM, Podda M, Beschmann HA, Pien C, Elliott PJ, Kaufmann R, Boemcke WH Pneumologie 2002 56 Suppl 1 S49
34. 473274 Proteasome inhibitor PS519 reduces superantigen-mediated T-cell activation severity of psoriasis in a SCID-Hu model. Zollner TM, Podda M, Beschmann HA, Diehl S, Pien C, Elliot PJ, Kaufmann R, Boehncke WH J Invest Dermatol 2001 117 3 768
35. 473278 Inhibition of proteasome reduces iNOS expression and behavioral dysfunction after intracerebral hemorrhage in rat. Al-Senani FM, Shirzadi A, Strong R, Elliot P, Grotta J, Aronowski J Neurology 2001 56 8 A368
36. 473279 Effects of PS-519 combined with thrombolytic therapy in embolic stroke in rat. Li Z, Zheng Z, Chopp M, Elliot PJ, Adams J Stroke 2001 32 1 351
37. 473280 Syntheses and biological evaluation of (+)-lactacystin and analogs. Masse CE, Morgan AJ, Adams J, Panek JS Eur J Org Chem 2000 14 2513-2528 A substantial and detailed reference discussing the chemical attributes of lactacystin and synthetic pathways. A detailed and well-commented description of MLN-519 synthesis.
38. 477233 Neuroprotection in acute ischaemic stroke: A tale of for whom the bell tolls? Gorelick PB Lancet 2000 355 9219 1925-1926
39. 477239 Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Samsa GP, Matchar DB Stroke 2001 32 3 669-674
40. 477241 Pathobiology of ischaemic stroke: An integrated view. Dirnagl U, Iadecola C, Moskowitz MA Trends Neurosci 1999 22 9 391-397
41. 477244 Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Di Napoli M, Papa F, Bocola V Stroke 2001 32 1 133-138
42. 477250 C-reactive protein in ischemic stroke: An independent prognostic factor. Di Napoli M, Papa F, Bocola V Stroke 2001 32 4 917-924
43. 477255 An essential role for NK-κB in preventing TNF-α-induced cell death. Beg AA, Baltimore D Science 1996 274 5288 782-784
44. 477265 NF-κB is activated and promotes cell death in focal cerebral ischemia. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M Nat Med 1999 5 5 554-559
45. 477268 Proteasome inhibitors: From in vitro uses to clinical trials. Rivett AJ, Gardner RC J Peptide Science 2000 6 9 478-488
46. 477271 A novel and efficient synthesis of a highly active analogue of clastrolactacystin β-lactone. Soucy F, Grenier L, Behnke M, Destree AT, McCormack TA, Adams JK, Plamondon L J Am Chem Soc 1999 121 43 9967-9976 This article details the synthesis and activity of MLN-519.
47. 477294 Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Gardner RC, Assinder SJ, Christie G, Mason GG, Markwell R, Wadsworth H, McLaughlin M, King R, Chabot-Fletcher MC, Breton JJ, Allsop D, Rivett AJ Biochem J 2000 346 Pt 2 447-454
48. 477297 Proteasome inhibition: A novel target for anti-stroke therapy. Elliott PJ, Shah I, Lees K, Pien C, Tortella F, Adams J Restorative Neurol Neurosci 2000 16 156
49. 477299 Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-κB activation, gliosis, and leukocyte infiltration. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, Tortella FC J Cereb Blood Flow Metab 2003 23 1 75-87 Paper reporting that proteasome inhibitors reduce neutrophil invasion of brain tissue after ischemia, dramatically improving neurological outcome and reducing infarct size.
50. 477300 Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB. Griscavage JM, Wilk S, Ignarro LJ Proc Natl Acad Sci USA 1996 93 8 3308-3312
51. 477301 Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injury. Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS, Nichols TC Am J Physiol-Heart Circulat Physiol 2003 284 3 H919-H926 This paper reports that MLN-519 was safe and effective in reducing reperfusion injury in a model of myocardial infarction in pigs.
52. 477302 Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons. Kikuchi S, Shinpo K, Takeuchi M, Tsuji S, Yabe I, Niino M, Tashiro K J Neurosci Res 2002 69 3 373-381
53. 477304 Proteasome inhibition results in increased poly-ADP-ribosylation: Implications for neuron death. Keller JN, Markesbery WR J Neurosci Res 2000 61 4 436-442
54. 477308 Dopamine induces proteasome inhibition in neural PC12 cell line. Keller JN, Huang FF, Dimayuga ER, Maragos WF Free Radic Biol Med 2000 29 10 1037-1042
55. 477311 Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, Stangl K Circulation 2002 105 4 408-410
56. 477312 Proteasomes and proteasome inhibition in the central nervous system. Ding Q, Keller JN Free Radic Biol Med A well-written update on proteasomes and proteasome inhibition in the central nervous systems.
57. 477316 Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. Keller JN, Huang FF, Zhu H, Yu J, Ho YS, Kindy TS J Cereb Blood Flow Metab 2000 20 10 1467-1473
58. 477321 NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons. Snider BJ, Tee LY, Canzoniero LM, Babcock DJ, Choi DW Eur J Neurosci 2002 15 3 419-428
59. 477324 Fibroblast cultures from healthy centenarians have an active proteasome. Chondrogianni N, Petropoulos I, Franceschi C, Friguet B, Gonos ES Exp Gerontol 2000 35 6-7 721-728
60. 477326 Age-dependent declines in proteasome activity in the heart. Bulteau AL, Szweda LI, Friguet B Arch Biochem Biophys 2002 397 2 298-304
61. 477330 The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon. El-Khodor BF, Kholodilov NG, Yarygina O, Burke RE Dev Brain Res 2001 129 1 47-56
62. 477333 Effects of proteasome inhibitors on the synaptic localization of Vesl-1S/Homer-1a proteins. Ageta H, Kato A, Fukazawa Y, Inokuchi K, Sugiyama H Brain Res Mol Brain Res 2001 97 2 186-189
63. 477387 Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1990 30 12 2752-2758
64. 479753 IκB-independent control of NF-κB activity by modulatory phosphorylations. Schmitz ML, Bacher S, Kracht M Trends Biochem Sci 2001 26 3 186-190